| 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism |
92 |
| 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction |
32 |
| 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer |
20 |
| 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism |
17 |
| The Colorful Diversity of Thyroid Hormone Metabolites |
14 |
| Vitamin D in Graves Disease: Levels, Correlation with Laboratory and Clinical Parameters, and Genetics |
10 |
| Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction |
9 |
| A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy |
8 |
| Effects of Chronic Lymphocytic Thyroiditis on the Clinicopathological Features of Papillary Thyroid Cancer |
7 |
| The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway |
7 |
| Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis |
7 |
| Thyroid Cancer Induction: Nitrates as Independent Risk Factors or Risk Modulators after Radiation Exposure, with a Focus on the Chernobyl Accident |
6 |
| Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma |
5 |
| Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study |
5 |
| In vivo Effects of Repeated Thyronamine Administration in Male C57BL/6J Mice |
5 |
| Moderate Frequency of Anti-Thyroglobulin Antibodies in the Early Phase of Subacute Thyroiditis |
5 |
| 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy |
5 |
| TRH Neurons and Thyroid Hormone Coordinate the Hypothalamic Response to Cold |
4 |
| Ultrasound Measurements of Thyroid Gland Volume at 36 Weeks' Corrected Gestational Age in Extremely Preterm Infants Born before 28 Weeks' Gestation |
4 |
| The Malignancy Risk Assessment of Cytologically Indeterminate Thyroid Nodules Improves Markedly by Using a Predictive Model |
4 |
| Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss? |
4 |
| Variables Contributing to Thyroid (Dys)Function in Pregnant Women: More than Thyroid Antibodies? |
4 |
| The Krakow Declaration on Iodine: Tasks and Responsibilities for Prevention Programs Targeting Iodine Deficiency Disorders |
4 |
| Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment |
4 |
| Indeterminate Thyroid Nodules: A Pragmatic Approach |
3 |
| Bethesda Classification and Cytohistological Correlation of Thyroid Nodules in a Brazilian Thyroid Disease Center |
3 |
| The Impact of Zoledronic Acid and Radioactive Iodine Therapy on Morbi-Mortality of Patients with Bone Metastases of Thyroid Cancer Derived from Follicular Cells |
3 |
| Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution |
3 |
| Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer |
3 |
| How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond? |
3 |
| Prevalence of Radiological Signs of Dysthyroid Optic Neuropathy in Magnetic Resonance Imaging in Patients with Active, Moderate-to-Severe, and Very Severe Graves Orbitopathy |
3 |
| Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study |
3 |
| European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries |
3 |
| Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan |
3 |
| Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature |
3 |
| CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma |
3 |
| Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria |
3 |
| Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand? |
3 |
| Evidence for Prenatal Exposure to Thyroid Disruptors and Adverse Effects on Brain Development |
3 |
| Differentiated Thyroid Cancer: How Do Current Practice Guidelines Affect Management? |
2 |
| Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials |
2 |
| Primary versus Tertiary Care Follow-Up of Low-Risk Differentiated Thyroid Cancer: Real-World Comparison of Outcomes and Costs for Patients and Health Care Systems |
2 |
| Parathyroid Hormone Assays following Total Thyroidectomy: Is There a Predictive Value? |
2 |
| Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye |
2 |
| Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience |
2 |
| Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience |
2 |
| Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report |
2 |
| Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives |
2 |
| Can Suspicious Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Cancer? |
2 |
| Liposarcoma of the Thyroid: A Case Report with a Review of the Literature |
2 |
